Proffitt & Goodson Inc Summit Therapeutics Inc. Transaction History
Proffitt & Goodson Inc
- $654 Million
- Q2 2025
A detailed history of Proffitt & Goodson Inc transactions in Summit Therapeutics Inc. stock. As of the latest transaction made, Proffitt & Goodson Inc holds 315 shares of SMMT stock, worth $8,772. This represents 0.0% of its overall portfolio holdings.
Number of Shares
315
Previous 215
46.51%
Holding current value
$8,772
Previous $4,000
50.0%
% of portfolio
0.0%
Previous 0.0%
Shares
2 transactions
Others Institutions Holding SMMT
# of Institutions
248Shares Held
87.6MCall Options Held
1.77MPut Options Held
2.49M-
Baker Bros. Advisors LP New York, NY24.4MShares$680 Million5.62% of portfolio
-
Vanguard Group Inc Valley Forge, PA11.6MShares$324 Million0.0% of portfolio
-
Black Rock Inc. New York, NY7.9MShares$220 Million0.0% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD6.56MShares$183 Million0.02% of portfolio
-
State Street Corp Boston, MA4.85MShares$135 Million0.0% of portfolio
About Summit Therapeutics Inc.
- Ticker SMMT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 201,215,008
- Market Cap $5.6B
- Description
- Summit Therapeutics Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat infectious diseases in the United States and Latin America. It conducts clinical programs focusing on Clostridioides difficile infection (CDI). The company's lead product candidate is ridinilazole, an orally administered small molecu...